Discover
IMMX
Immix Biopharma, Inc.
9.55
1 x 9.53
2 x 9.54
bid
ask
-
0.02
0.20%
12:05 PM
timesize
| Ytd | 82.61% | |
| 1y | 235.11% |
9.37
day range
9.79
1.94
52 week range
12.14
| Open | 9.78 | Prev Close | 9.57 | Low | 9.37 | High | 9.79 | Mkt Cap | 520.63M |
| Vol | 573.88K | Avg Vol | 1.62M | EPS | -0.91 | P/E | -10.52 | Forward P/E | -3.96 |
| Beta | 0.09 | Short Ratio | 2.94 | Inst. Own | 17.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 9.49 | 200-d Avg | 7.15 | 1yr Est | 7.00 |
| Income Statement | |||
| Operating Expenses | 10.80M | ||
| Research and Development Expense | 5.98M | ||
| Selling, General and Administrative Expense | 4.82M | ||
| Operating Income | -10.80M | ||
| Net Income | -10.09M | ||
| Net Income Common Stock | -10.09M | ||
| Net Income Common Stock (USD) | -10.09M | ||
| Consolidated Income | -10.09M | ||
| Earnings per Basic Share | -0.18 | ||
| Earnings per Basic Share (USD) | -0.18 | ||
| Earnings per Diluted Share | -0.18 | ||
| Earning Before Interest & Taxes (EBIT) | -10.09M | ||
| Earning Before Interest & Taxes (USD) | -10.09M | ||
| Weighted Average Shares | 55.37M | ||
| Weighted Average Shares Diluted | 55.37M | ||
| Balance Sheet | |||
| Cash and Equivalents | 79.25M | ||
| Cash and Equivalents (USD) | 79.25M | ||
| Investments | 11.33M | ||
| Investments Current | 11.33M | ||
| Current Assets | 92.27M | ||
| Property, Plant & Equipment Net | 3.36M | ||
| Total Assets | 95.82M | ||
| Debt Current | 125.39K | ||
| Total Debt | 1.04M | ||
| Current Liabilities | 10.54M | ||
| Debt Non-Current | 912.34K | ||
| Total Liabilities | 11.45M | ||
| Accumulated Retained Earnings (Deficit) | -114.55M | ||
| Accumulated Other Comprehensive Income | 105.64K | ||
| Shareholders Equity | 84.36M | ||
| Shareholders Equity (USD) | 84.36M | ||
| Assets Non-Current | 3.54M | ||
| Total Debt (USD) | 1.04M | ||
| Liabilities Non-Current | 912.34K | ||
| Trade and Non-Trade Payables | 10.41M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 130.77K | ||
| Net Cash Flow from Financing | -37.56K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -14.68M | ||
| Capital Expenditure | -32.49K | ||
| Issuance (Purchase) of Equity Shares | 33.53K | ||
| Net Cash Flow from Investing | -4.80M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -4.77M | ||
| Net Cash Flow from Operations | -9.83M | ||
| Effect of Exchange Rate Changes on Cash | -12.81K | ||
| Share Based Compensation | 575.57K | ||